The recently published FLOW trial, which specifically targeted T2DM patients with CKD and used kidney-specific primary endpoints, has solidified the efficacy of GLP-1 RAs in slowing CKD progression [58]
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
Yes, some (Skin lightening) skin wightening creams cause side effects, especially if they contain harsh chemicals or are used incorrectly
doi:10.1016/j.clpt.2005.09.009
Current guidelines tend to prioritize starting a GLP-1 medication for people who already have cardiovascular or kidney disease, or for those where weight management is a concern
But here's the twist: when the glucagon receptor is activated in conjunction with GLP-1, particularly at higher doses, it can lead to increased energy expenditure and direct effects on liver fat reduction
